The CAG was registered as one of the National Institutes of Health (NIH) Rare Diseases Clinical Research Consortia and acquired a new designation, “Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA).” Upon conclusion of the 2-years natural history study of SCA1, SCA2, SCA3, and SCA6, the CRC-SCA changed the acronym for SCA to “Studies of Cerebellar Ataxia” under NAF sponsorship. This evidence concerns the gene ATXN3 and colorectal carcinoma.